title: Erectile dysfunction: interrelationship with the metabolic syndrome.
abstract: Erectile dysfunction (ED) is more commonly seen in men with various components of the metabolic syndrome (a constellation of various cardiovascular and diabetes risk factors). ED can be considered as a risk marker of the metabolic syndrome and its associated conditions. The patient with ED should be thoroughly evaluated for coexisting vascular disease. Any cardiovascular risk factors should be modified or treated (ie, smoking, diabetes, hypertension, and hyperlipidemia). Endothelial dysfunction is a major unifying etiology for many of the aspects of the metabolic syndrome, especially diabetes and cardiovascular disease. It also plays a major role in ED. The multifactorial etiology of ED, especially in patients with the metabolic syndrome, increases the complexity of managing this problem so clinicians need to be aware of the underlying pathophysiology to ensure the best possible outcomes in management.
authors.affiliation: Global Clinical Research, Novartis Pharmaceuticals, One Health Plaza, East Hanover, NJ 07936-1080, USA. glenn.matfin@pharma.novartis.com
authors.forename: Glenn
authors.initials: G
authors.lastname: Matfin
authors.forename: Ali
authors.initials: A
authors.lastname: Jawa
authors.forename: Vivian A
authors.initials: VA
authors.lastname: Fonseca
mesh_terms: D015415:Biomarkers / Q000097:blood; D003925:Diabetic Angiopathies / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000503:physiopathology; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000503:physiopathology*; D009765:Obesity; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D008055:Lipids; D010726:Phosphodiesterase Inhibitors